Abstract
2065Background: Antiangiogenic agents targeting new blood vessel formation are approved to treat progressive glioblastoma (GBM), but limited data are available on the activity of vascular disrupting agents targeting established blood vessels in these tumors. Prostate specific membrane antigen (PSMA) is a transmembrane peptidase upregulated on endothelial cells of solid tumors including GBM, making it a potential therapeutic target. A PSMA-targeted monoclonal antibody conjugated with microtubule disrupting agent monomethyl auristatin E (MMAE) is undergoing evaluation in advanced prostate cancer (PSMA ADC, Progenics Pharmaceuticals). Unconjugated MMAE has demonstrated activity against GBM cell lines. Methods: We investigated the activity of PSMA ADC in a single arm Phase II study in progressive GBM patients following prior treatment with radiation, temozolomide and bevacizumab. 2.5 mg/kg PSMA ADC was administered intravenously every 3 weeks until disease progression, unacceptable toxicity or removal from st...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
